mAbs

MONTREAL, QUEBEC -- (Marketwire - September 07, 2010) - Alethia Biotherapeutics Inc., a privately held Montreal-based biopharmaceutical company focused on the development of monoclonal antibodies ( "mAbs") against therapeutic targets emanating from its STAR proprietary target discovery platform, announced today it has closed a C$9. 6M Series A round of financing.

BioSpace.com Featured News and Stories 2010

Human Immunodeficiency Virus, see HIV human monoclonal antibodies mAbs, 324

OUR BODIES, OURSELVES The Boston Women’s Health Book Collective 2005

Examples of this new focus include new vaginal microbicides and human monoclonal antibodies mAbs that prevent both pregnancy and STIs, including HIV/AIDS.

OUR BODIES, OURSELVES The Boston Women’s Health Book Collective 2005

Yet today, even Avastin, one of the most widely heralded mAbs of our time, isn't very effective at all without toxic chemotherapy in combination.

unknown title 2011

("Hengrui"), a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner ("ChemPartner"), a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies ("mAbs").

unknown title 2011

Through the partnership, ChemPartner and Hengrui will initially collaborate on the development of novel therapeutic mAbs in a major therapeutic area.

unknown title 2011

These mAbs bind to the most sensitive part of the TCR, suggesting how the relay of TCR signals operates via its various component parts.

Biosingularity Snowcrash 2010

"Our findings with mAbs demonstrate that TCR activation function depends on the angle at which anti-CD3 mAb binding takes place," says the study's lead author, Sun Taek Kim, PhD, of Dana-Farber and Harvard.

Biosingularity Snowcrash 2010

First, immunologists identified monoclonal antibodies (mAbs) that target a portion of the TCR - known as CD3 subunits - involved in T cell activation.

Biosingularity Snowcrash 2010

Cells were then incubated with specific mAbs at 4°C for 30 min in dark.

PLoS ONE Alerts: New Articles Xiaoling Gao et al. 2010